Universität zu Köln

2022

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P. and Westin, J. R. (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N. Engl. J. Med., 386 (7). S. 629 - 640. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

2020

Andreadis, C., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Foley, S. R., Westin, J. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Salles, G. A., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Wagner-Johnston, N. D., Kato, K., Corradini, P., Tiwari, R., Awasthi, R., Lawniczek, T., Eldjerou, L. K. and Kersten, M. J. (2020). Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncol. Res. Treat., 43 (SUPPL 4). S. 62 - 64. BASEL: KARGER. ISSN 2296-5262

Westin, J., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Andreadis, C., Foley, S. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Kersten, M. J., Wagner-Johnston, N. D., Kato, K., Corradini, P., Han, X., Tiwari, R., Eldjerou, L. K., Pacaud, L. B. and Salles, G. A. (2020). Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 58 - 59. BASEL: KARGER. ISSN 2296-5262

2018

Borchmann, P., Tam, C. S., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S. M., Bishop, M. R., Andreadis, C., Foley, S. R., Westin, J. R., Fleury, I., Ho, P. J., Mielke, S., Salles, G., Maziarz, R. T., Anak, Oe, Pacaud, L. B., del Corral, C., Awasthi, R., Agoulnik, S., Tai, F. and Schuster, S. J. (2018). An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncol. Res. Treat., 41. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262

2017

Schuster, S. J., Bishop, M. R., Tam, C., Waller, E. K., Borchmann, P., McGuirk, J., Jaeger, U., Jaglowski, S., Andreadis, C., Westin, J., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Anak, O., Pacaud, L., Awasthi, R., Tai, F., Salles, G. and Maziarz, R. T. (2017). GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - AN INTERIM ANALYSIS. Haematologica, 102. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078